NSNair Seixas

Nair Seixas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nair Seixas has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Mendes Dias

    Institute of Molecular Pathology and Immunology, University of Porto , Porto

    1 shared publication
  • Cláudia Sousa Rodrigues

    Institute of Molecular Pathology and Immunology, University of Porto , Porto

    1 shared publication
  • Inês Alves

    Institute for Research and Innovation in Health (i3s), University of Porto, 4200-135 Porto, Portugal

    1 shared publication
  • Joana Gaifem

    Institute of Molecular Pathology and Immunology, University of Porto , Porto

    1 shared publication
  • José Oliveira

    Research Center in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, 4200-450 Porto, Portugal

    1 shared publication
  • Luis Malheiro

    Departamento de Doenças Infeciosas, Centro Hospitalar Vila Nova de Gaia/Espinho , Gaia

    1 shared publication

Latest Publications

  • SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis

    by Inês Alves, Manuel Machado Vicente, Joana Gaifem, Ângela Fernandes, Ana Mendes Dias, Cláudia Sousa Rodrigues, José Carlos Oliveira, Nair Seixas, Luis Malheiro, Miguel Araújo Abreu, et al.

    COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. Key Points T cells from COVID-19 patients display less complex N-glycans at diagnosis. IL-2 is a putative driver of glycan switch in COVID-19 patients. DC-SIGN expression in monocytes at diagnosis predicts poor disease course.